Summary A study was started in 1976 whereby patients with Stage II and operable Stage III MBC were given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy. The rarity of the disease precluded a randomised trial. Thirty-nine patients are available for analysis at a median follow-up of 49 months. The actuarial survival of the Tamoxifen treated patients is 61% (range 42-80%) at 5 years compared to 44% (range 35-53%) for historical controls (P = 0.006). Disease-free survival was 56% (37-75%) vs 28% (17-33%) at 5 years (P = 0.005). There were no serious side-effects recorded. The conclusion from this, the first reported series on adjuvant Tamoxifen therapy for MBC, is that significant improvement in disease-free survival can be achieved with minimal upset to the patients. Recruitment to the study continues.
The drug Tamoxifen has been used world-wide as adjuvant therapy for carcinoma of the female breast. While individual patients with male breast carcinoma (MBC) may have been given adjuvant Tamoxifen, to the authors' knowledge, no documented series has been published on the efficacy of the drug used as adjuvant therapy in this group of patients. The reason for this is probably the obvious one, the rarity of the disease. Even with multi-centre co-operation it is unlikely that sufficient patients would be available to carry out a randomised clinical trial.
In a previous paper (Ribeiro, 1983) , it was shown that a 37.5% objective regression rate had been obtained in the treatment of advanced MBC with Tamoxifen. In a further paper (Ribeiro, 1985) , it was reported that oestrogen and progesterone receptors had been measured in the primary tumours of 16 patients by the dextran charcoal method previously described by Barnes et al. (1977) . Thirteen of the 16 primary tumours (81%) showed positive oestrogen or progesterone activity.
Particularly poor survival rates ranging from 17% to 28% have been reported for node positive MBC (Crichlow, 1974; Yap et al., 1979 Two of the patients had previously been treated for basal cell carcinomata of the skin and one patient was successfully treated for a squamous cell carcinoma of the lung, 4 years previously, by means of a partial lobectomy.
Unfortunately hormone receptor assays were done on the primary tumours of five paitents only. By using the dextran charcoal method, four of the tumours were positive for both oestrogen and progesterone receptors and one was negative.
The age of the youngest patient entered in the present study was 39 years and the oldest patient 78 years, with a mean of 62 years.
Nineteen of the patients were classified as having Stage II disease and 20 as having Stage III disease.
Nine patients had a modified radical mastectomy carried out and 30 had a simple (total) mastectomy with node sampling of the axilla. All 30 patients who had a simple mastectomy had postoperative radiotherapy to the chest wall and regional lymph node areas. Three of the patients had a radical mastectomy and post-operative radiotherapy.
The Group, 1988) .
In this report it was suggested that patients given adjuvant Tamoxifen for 2 years or more had a better disease-free survival than those given the drug for 1 year. It was therefore proposed to give Tamoxifen to male breast patients entered in the study from 1988 onwards, for a period of 2 years.
Statistics
Overall survival and disease-free survival curves were calculated by the Kaplan-Meier method. Confidence intervals were obtained by using Greenwood's formula (Armitage & Berry, 1987) . Curves were compared by using the logrank test (Peto & Peto, 1972) . Disease-free survival was measured from the date adjuvant Tamoxifen was commenced to the date when one of the following occurred; recurrence of breast carcinoma on the chest wall or regional lymph nodes, or distant metastases or censored time to death without evidence of recurrence.
No patients was lost to follow-up. The shortest follow-up was 12 months and the longest 135 months with a median of 49 months, the reason for this being that a substantial number of patients have been entered into the study in the last 3 years. 
Results
Of the 39 patients given adjuvant Tamoxifen, two patients stopped the drug due to side-effects; one patient developed alopecia and the other a persistent skin rash. Seven patients had their Tamoxifen therapy changed following relapse of their disease. The remaining 30 patients completed their course of adjuvant Tamoxifen without modification.
The measured hormonal profiles fell within the normal ranges outlined above in all patients except the patient with Klinefelter's Syndrome. The findings in the latter patient receive adjuvant Tamoxifen. Only deaths from breast cancer have been considered, patients dying from other causes being censored. The actuarial suirvival at 5 years of the adjuvant treated of the adjuvant treated patients is 61% (range 42% to 80%) vs 44% (range 35% to 53%) for the historical controls. (P = 0.006). The disease-free survival of the adjuvant patients was 56% (range 37% to 75%) at 5 years compared to 25% (range 17% to 33%) for the controls (P = 0.0005) as shown in Figure 1 .
One of the major problems that exists when making comparisons with historical controls treated over a long period of time is that the survival of the controls treated in the last decade may be significantly better than that of the patients treated three to four decades ago.
In Figure 2 is shown the disease-free survival of the 39 adjuvant Tamoxifen patients compared with patients treated between 1942-59, 1960-69, and 1970-75 . An attempt was also made to match the control patients as far as possible with the adjuvant Tamoxifen group with regard to age, stage, and type of primary treatment.
The disease-free survival of the adjuvant Tamoxifen group is not only significantly better than that of the patients treated before 1970, but also better than that of the patients treated after 1970 and not given adjuvant Tamoxifen (overall chi-square = 11.78 on 3DF. P = 0.006).
Discussion
In Western Europe and in America, the majority of women with breast cancer now present with Stage I disease. Furthermore, within that category, the tendency is to find more primary tumours less than 2 cm in diameter when a National screening programme is in place.
With all the publicity in relation to early detection in breast cancer directed to the female population, it is not surprising that the trend towards earlier presentation of breast cancer in females, has not been mirrored in males. Scheike (1973) (Ribeiro, 1985) the proportions were 38% Stage I, 21% as Stage II and 26% as Stage III.
Adjuvant hormone and chemotherapy for node positive breast cancer in females has been routinely prescribed for at least 20 years. No series using adjuvant hormone therapy for MBC has been published. The first report of the use of adjuvant chemotherapy for node positive MBC appeared in 1987 (Bagley et al., 1987 However, since this analysis was completed, two patients with Klinefelter's Syndrome have been started on adjuvant Tamoxifen. After 6 months of treatment, there has been no alteration in their hormonal profiles.
In an earlier report (Ribeiro et al., 1980) Fisher et al., 1989) both of which advocated adjuvant Tamoxifen given for 5 years to female breast cancer patients as being more efficacious than Tamoxifen given for for a shorter period. If these results are confirmed, it might be within the bounds of reason to suggest that node positive patients with MBC be given Tamoxifen for an indefinite period following diagnosis of the disease.
